bb2aaaaf-74b9-4825-b9c2-9011bc50d0b3.jpeg
8ed82ead-4910-4c02-809e-836d18a6c3da.jpeg
Explain everything on this drug profile why those conditions are contraindicated for this drug why they are in precaution and explain why the adrs are caused
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
I now have sufficient information from authoritative textbook sources to write a thorough explanation. Here is the complete breakdown:
Chlorpromazine (Serectil / Yemetil) - Full Drug Profile Explanation
Generic: Chlorpromazine | Class: Phenothiazine derivative | Category: First-generation (typical) antipsychotic
MOA: Blocks D2 (dopamine 2) receptors in the mesolimbic pathway, reducing excess dopaminergic activity, which reduces the positive symptoms of psychosis (hallucinations, delusions, thought disorder). Crucially, chlorpromazine also blocks many other receptors - this "large action" profile is the root cause of most of its ADRs and precautions. - Stahl's Essential Psychopharmacology, p.217
CONTRAINDICATIONS - Why Each is Absolute
1. Hypersensitivity
Straightforward - prior allergic or anaphylactic reaction to chlorpromazine or any phenothiazine is an absolute barrier to re-exposure. Cross-reactivity exists across the phenothiazine class.
2. Pre-existing CNS Depression
Chlorpromazine blocks H1 (histamine-1), muscarinic (M1), and alpha-1 adrenergic receptors in addition to D2. Each of these contributes to CNS depression and sedation. If a patient already has CNS depression (e.g. from opioids, barbiturates, head injury, hepatic encephalopathy), adding chlorpromazine causes additive, potentially fatal CNS and respiratory depression. The drug's sedative action cannot be safely stacked onto pre-existing CNS suppression. - Rosen's Emergency Medicine, p. (block 28)
3. Coma
A comatose patient has maximal CNS depression. Chlorpromazine's multi-receptor depressant effects (alpha-1 blockade → hypotension, H1 blockade → deeper sedation, sodium channel blockade → cardiac dysrhythmia) would worsen hemodynamic instability, deepen unresponsiveness, and risk respiratory collapse. There is no benefit to antipsychotic therapy in an unconscious patient.
4. Bone Marrow Suppression
Phenothiazines are known to cause agranulocytosis and leukopenia - a direct toxic effect on bone marrow progenitor cells. If bone marrow is already suppressed (from chemotherapy, aplastic anemia, or another drug), adding chlorpromazine multiplies the risk of life-threatening neutropenia, leaving the patient with no immune defence. - Kaplan & Sadock's, block 60
5. Pheochromocytoma
This is a catecholamine-secreting adrenal tumor. Chlorpromazine blocks alpha-1 adrenergic receptors, which would normally seem helpful in hypertension - but it is contraindicated because phenothiazines can cause paradoxical severe hypertensive crisis in pheochromocytoma. The mechanism: alpha-1 blockade lowers peripheral resistance and triggers a reflex surge of catecholamines from the tumor via baroreceptor activation; since beta-receptors remain unblocked, this catecholamine surge causes overwhelming beta-mediated vasoconstriction and tachycardia. Phenothiazines are explicitly listed as first-line agents to avoid in pheochromocytoma hypertensive crisis in Tintinalli's Emergency Medicine. - Tintinalli's EM, block 5
6. Lactation
Chlorpromazine is highly lipophilic and crosses into breast milk. The infant has an immature blood-brain barrier and undeveloped hepatic metabolism, making them extremely vulnerable to CNS depression, sedation, and extrapyramidal effects from even trace exposure. It is absolutely avoided during breastfeeding.
PRECAUTIONS - Why Each Requires Caution (Not Absolute Stop)
1. Parkinson's Disease
Parkinson's disease is caused by degeneration of the nigrostriatal dopamine pathway - these patients already have critically low dopamine transmission in the basal ganglia. Chlorpromazine blocks D2 receptors in the nigrostriatal pathway (in addition to the mesolimbic pathway), which severely worsens parkinsonian symptoms - rigidity, tremor, bradykinesia, and postural instability. It does not cause Parkinson's, but it dramatically unmasks and worsens it. Antipsychotic use is not impossible in PD (e.g. for psychosis from levodopa), but requires extreme caution and preferably a quetiapine or clozapine which has lower D2 nigrostriatal affinity.
2. Cardiovascular (CV) Disease
Chlorpromazine, as a phenothiazine, is structurally related to tricyclic antidepressants (TCAs) and shares their sodium channel blocking and potassium channel (delayed rectifier) blocking properties. This results in:
- QTc prolongation → risk of torsades de pointes
- Wide-complex dysrhythmias (like a TCA overdose pattern)
- Alpha-1 blockade → orthostatic hypotension
In a patient with pre-existing CV disease (arrhythmia, heart failure, ischemic heart disease), these effects are far more dangerous and the risk of sudden death is significantly higher. Antipsychotics are directly associated with increased risk of sudden cardiac death, worsened by comorbid cardiac disease. - Rosen's EM, block 28
3. Renal and Hepatic Impairment
Chlorpromazine is extensively metabolised in the liver (CYP450-mediated, primarily CYP2D6 and CYP3A4) and its metabolites are renally excreted. In hepatic impairment, the drug accumulates to toxic levels causing excessive sedation, CNS depression, and increased ADR burden. In renal impairment, active metabolites accumulate. Dose reduction and careful monitoring are needed rather than complete avoidance.
4. Cerebrovascular and Respiratory Disease
- Cerebrovascular disease: Alpha-1 blockade causes orthostatic hypotension, which in a patient with already compromised cerebral blood flow can precipitate strokes or TIAs. Elderly patients with cerebrovascular disease are at particular risk.
- Respiratory disease: The CNS-depressant and anticholinergic properties of chlorpromazine can suppress the respiratory drive and thicken bronchial secretions, worsening conditions like COPD or asthma.
5. Jaundice
Chlorpromazine is a well-known cause of cholestatic jaundice (an idiosyncratic hypersensitivity reaction in the bile ducts). Using it in a patient with pre-existing hepatic/biliary disease or jaundice risks worsening hepatic dysfunction and producing severe cholestasis.
6. Diabetes Mellitus (DM)
Antipsychotics cause hyperglycemia and insulin resistance through multiple mechanisms:
- Direct antagonism at 5-HT2C receptors disrupts insulin secretion signalling
- Weight gain from H1 blockade and 5-HT2C blockade worsens insulin resistance
- Some evidence suggests a direct pharmacological effect on pancreatic beta cells independent of weight gain (acute hyperglycemia has been reported before significant weight gain occurs)
In a diabetic patient, these effects destabilise glycaemic control and increase the risk of diabetic ketoacidosis (DKA) and hyperosmolar states. - Kaplan & Sadock's, block 43
7. Hypothyroidism
Hypothyroid patients have slowed metabolism, baseline CNS depression, bradycardia, and altered drug clearance. Chlorpromazine's sedative effects and cardiac effects (bradycardia, QTc prolongation) are potentiated. Hypothyroidism also slows hepatic drug metabolism, increasing drug accumulation.
8. Pregnancy
Chlorpromazine crosses the placenta. First trimester exposure carries a theoretical teratogenicity risk. Late-trimester or peripartum exposure can cause neonatal extrapyramidal symptoms (neonatal drug-withdrawal EPS: tremor, rigidity, poor feeding) and neonatal sedation/respiratory depression in the newborn. It is not an absolute contraindication (schizophrenia must still be treated in pregnancy), but risk-benefit assessment is essential.
ADVERSE DRUG REACTIONS (ADRs) - Mechanisms Explained
All ADRs map directly to the receptor-binding profile of chlorpromazine.
| ADR | Receptor/Mechanism |
|---|---|
| Tardive Dyskinesia (long-term) | Chronic D2 blockade in the nigrostriatal pathway causes compensatory D2 receptor upregulation and hypersensitivity. When the drug is stopped or even continued, hypersensitive receptors respond abnormally to dopamine bursts - producing orofacial and limb choreiform movements. This is irreversible in many cases. |
| Involuntary movements of extremities (EPS / Parkinsonism) | D2 blockade in the nigrostriatal pathway mimics dopamine deficiency → drug-induced Parkinsonism (tremor, rigidity, bradykinesia) and dystonia (sudden muscle spasms). |
| Dry mouth | Muscarinic (M1) receptor blockade inhibits salivary gland secretion - saliva production requires cholinergic stimulation. |
| Constipation | M1 blockade in the gut reduces peristalsis. Cholinergic innervation normally drives bowel motility; blocking it slows the GI tract. |
| Urinary retention | M1/M3 blockade in the detrusor muscle of the bladder prevents normal cholinergic-mediated contraction during voiding. The bladder cannot empty properly. |
| Insomnia | Paradoxical effect - while the drug is broadly sedating acutely, chronic D2 blockade disrupts dopamine-dependent reward and arousal circuits; dopamine has a role in maintaining normal sleep architecture. Some patients experience rebound insomnia. Also, akathisia (motor restlessness from EPS) prevents sleep. |
| Depression | D2 blockade in the mesocortical pathway (the "reward" and motivation circuit) reduces dopaminergic tone in the prefrontal cortex, blunting emotional response and motivation, producing a drug-induced depressive/anhedonic state (neuroleptic dysphoria). |
| Convulsions | Chlorpromazine lowers the seizure threshold - it blocks inhibitory dopaminergic pathways and disrupts neuronal excitability thresholds through sodium channel effects. |
| Weight gain | H1 (histamine-1) blockade in the hypothalamus disrupts satiety signalling, increasing appetite. 5-HT2C blockade also reduces satiety and increases food intake. Chlorpromazine is one of the higher-risk antipsychotics for weight gain due to strong H1 affinity. |
| Hyperglycemia and raised cholesterol | Weight gain increases insulin resistance. Additionally, 5-HT2C blockade directly impairs insulin secretion. Dyslipidaemia occurs due to altered fat metabolism from H1/5-HT2C disruption and fat redistribution associated with metabolic syndrome from antipsychotic use. - Kaplan & Sadock's, block 43; Goodman & Gilman's, block 5 |
DRUG INTERACTIONS - Mechanisms
| Interaction | Mechanism |
|---|---|
| Anticholinergics, antiparkinson agents, TCAs | All three classes have their own anticholinergic (M1 blocking) properties. Combined with chlorpromazine's muscarinic blockade → additive anticholinergic crisis: tachycardia, hyperthermia, delirium, ileus, urinary retention |
| MAOIs | Additive orthostatic hypotensive effect - both MAOIs and chlorpromazine (via alpha-1 blockade) reduce vasomotor tone; combined use causes dangerous postural hypotension |
| Guanethidine, methyldopa, clonidine | Chlorpromazine reverses the antihypertensive effect - it blocks the neuronal uptake or receptor action of these drugs (guanethidine is displaced from nerve terminals; alpha-agonist effects of clonidine/methyldopa are blunted), paradoxically raising blood pressure |
| Sedatives, hypnotics, antihistamines, general anaesthetics, opiates, alcohol | Additive CNS depressant effect - all these agents depress CNS function; chlorpromazine's H1 blockade and direct CNS depression summates with these agents, risking excessive sedation, respiratory depression, and coma |
Key takeaway: The entire ADR and contraindication profile of chlorpromazine flows from its multi-receptor promiscuity: therapeutic effects come from D2 mesolimbic blockade, while side effects arise from D2 nigrostriatal blockade (EPS, tardive dyskinesia), M1 blockade (anticholinergic effects), H1 blockade (sedation, weight gain), alpha-1 blockade (hypotension), and sodium/potassium channel blockade (cardiac dysrhythmias). Understanding this receptor map makes every entry on this drug profile predictable and logical.
- Stahl's Essential Psychopharmacology, pp. 217-218
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry, block 60
- Rosen's Emergency Medicine, block 28
- Goodman & Gilman's Pharmacological Basis of Therapeutics, block 5
- Tintinalli's Emergency Medicine, blocks 5 & 24
This is a shared conversation. Sign in to Orris to start your own chat.